PubMed Review

July 2022

PubMed Review of the Most relevant research on Lung Cancer

SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING

Expert opinion on NSCLC small specimen biomarker testing – Part 1: Tissue collection and management Virchows Arch. 2022 Jul 20. doi: 10.1007/s00428-022-03343-2. Online ahead of print. Frédérique Penault-Llorca  1 , Keith M Kerr  2 , Pilar Garrido  3 , et al. DOI: 10.1007/s00428-022-03343-2

A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting J Natl Cancer Inst. 2022 Jul 12;djac127. doi: 10.1093/jnci/djac127. Online ahead of print. Kathryn L Taylor  1 , Randi M Williams  1 , Tengfei Li  2 , George Luta  2 , Laney Smith  1 , Kimberly M Davis  1 , Cassandra Stanton  3 , Raymond Niaura  4 , David Abrams  4 , Tania Lobo  1 , Jeanne Mandelblatt  1 , Jinani Jayasekera  1 , Rafael Meza  5 , Jihyoun Jeon  5 , Pianpian Cao  5 , Eric D Anderson  6 , Georgetown Lung Screening, Tobacco, and Health Trial

Molecular biomarkers and liquid biopsies in lung cancer Semin Oncol. 2022 Jul 3;S0093-7754(22)00047-1. doi: 10.1053/j.seminoncol.2022.06.007. Online ahead of print. Kamya Sankar  1 , Mina Zeinali  2 , Sunitha Nagrath  2 , Nithya Ramnath  3

Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility Cancer Med. 2022 Jul 24. doi: 10.1002/cam4.5066. Online ahead of print. Kristin G Maki  1 , Rajesh Talluri  2 , Iakovos Toumazis 1 , Sanjay Shete  3  4   5 , Robert J Volk  1

Challenges in initiating a lung cancer screening program: Experiences from two VA medical centers Semin Oncol. 2022 Jul 3;S0093-7754(22)00046-X. doi: 10.1053/j.seminoncol.2022.06.006. Online ahead of print. Stephen Bujarski  1 , Robert Flowers  2 , Mansour Alkhunaizi  3 , Dave Cuvi  4 , Sneha Sathya  5 , Jennifer Melcher  6 , Farrah Kheradmand  7 , Gregory Holt  8

Expert opinion on NSCLC small specimen biomarker testing – Part 2: Analysis, reporting, and quality assessment Virchows Arch. 2022 Jul 20;1-16. doi: 10.1007/s00428-022-03344-1. Online ahead of print. Frédérique Penault-Llorca  1 , Keith M Kerr  2 , Pilar Garrido  3 , Erik Thunnissen  4 , Elisabeth Dequeker  5 , Nicola Normanno  6 , Simon J Patton  7 , Jenni Fairley  8 , Joshua Kapp  9 , Daniëlle de Ridder  10 , Aleš Ryška  11 , Holger Moch  12

National Cancer Institute Smoking Cessation at Lung Examination Trials Brief Report: Baseline Characteristics and Comparison With the U.S. General Population of Lung Cancer Screening-Eligible Patients JTO Clin Res Rep. 2022 Jun 3;3(7):100352. doi: 10.1016/j.jtocrr.2022.100352. eCollection 2022 Jul. Rafael Meza  1 , Jihyoun Jeon  1 , Evelyn Jimenez-Mendoza  1 , et al.

NSCLC SURGERY

Optimal Chest Drainage Method After Anatomical Lung Resection: A Prospective Observational Study Ann Thorac Surg. 2022 Jul 19;S0003-4975(22)00971-7. doi: 10.1016/j.athoracsur.2022.06.042. Online ahead of print. Hiroyuki Adachi  1 , Shin Wakimoto  2 , Kohei Ando  3 , Taketsugu Yamamoto 4 , Yuichi Saito  5 , Satoshi Shiono  6 , Tekkan Woo  7 , Hiroyuki Ito  8 , Yukinori Sakao  5 , Noriyoshi Sawabata  9

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients J Thorac Dis. 2022 Jun;14(6):2357-2386. doi: 10.21037/jtd-21-1824. Frank C Detterbeck  1 , Vincent J Mase Jr  1 , Andrew X Li  2 , Ulas Kumbasar  3 , Brett C Bade  4 , Henry S Park  5 , Roy H Decker 5, David C Madoff  6 , Gavitt A Woodard 1  Whitney S Brandt  7 , Justin D Blasberg  1

Pulmonary completion lobectomy after segmentectomy: An integrated analysis of perioperative outcomes Thorac Cancer. 2022 Jul 5. doi: 10.1111/1759-7714.14565. Online ahead of print. Yu-Wei Liu  1   2   3 , Chieh-Ni Kao  1 , Hung-Hsing Chiang  1   3 , Jui-Ying Lee  1 , Hsien-Pin Li  1 , Po-Chih Chang  1   2 , Shah-Hwa Chou  1   2

Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer Ann Am Thorac Soc. 2022 Jul 11. doi: 10.1513/AnnalsATS.202203-275OC. Online ahead of print. Qian Wang  1 , Kimberly Stone  2 , Jeffrey A Kern  3 , Christopher G Slatore  4   5   6 , Scott Swanson  7 , William Blackstock Jr  8 , Rabia Saeed Khan  9 , Cardinale B Smith  10 , Rajwanth R Veluswamy  10 , Mark Chidel  11 , Juan P Wisnivesky  12

Brief Report: Contralateral Lobectomy for Second Primary NSCLC: Perioperative and Long-Term Outcomes JTO Clin Res Rep. 2022 Jun 18;3(8):100362. doi: 10.1016/j.jtocrr.2022.100362. eCollection 2022 Aug. Jennie K Choe  1 , Amy Zhu  1 , Alexander J Byun  1 , et al.

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors J Thorac Dis. 2022 Jun;14(6):2387-2411. doi: 10.21037/jtd-21-1825. Brett C Bade  1 , Justin D Blasberg  2 , Vincent J Mase Jr  2 , Ulas Kumbasar  3 , Andrew X Li  4 , Henry S Park  5 , Roy H Decker  5 , David C Madoff  6 , Whitney S Brandt  7 , Gavitt A Woodard  2 , Frank C Detterbeck  2

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma J Transl Med. 2022 Jul 25;20(1):332. doi: 10.1186/s12967-022-03520-6. Nan Sun #  1   2 , Yuejun Luo #  1   2 , et al.

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202) Front Med. 2022 Jul 16. doi: 10.1007/s11684-021-0916-8. Online ahead of print. Jianhua Shi  1 , Ying Cheng  2 , Qiming Wang  3 , Kai Li  4 , Lin Wu  5 , Baohui Han  6 , Gongyan Chen  7 , Jianxing He  8 , Jie Wang  9 , Haifeng Qin  10 , Xiaoling Li  11

Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung Clin Lung Cancer. 2022 Jun 21;S1525-7304(22)00146-2. doi: 10.1016/j.cllc.2022.06.002. Online ahead of print. Edgardo S Santos  1 , Estelamari Rodriguez  2

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis Transl Cancer Res. 2022 Jun;11(6):1472-1482. doi: 10.21037/tcr-22-71. Xian Xiao #  1   2   3 , Guixing Zhang #  1   2   3 , Binxu Sun  1   2 , Chaoran Wang  1   2   3 , Xiaoqun Wang  1   2 , Fanming Kong  1   2 , Yingjie Jia  1   2

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC JTO Clin Res Rep. 2022 Jun 25;3(8):100367. doi: 10.1016/j.jtocrr.2022.100367. eCollection 2022 Aug. Dong-Wan Kim  1 , Shirish Gadgeel  2 , Scott N Gettinger  3 , et al.

Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning? Curr Oncol. 2022 Jul 7;29(7):4779-4790. doi: 10.3390/curroncol29070379. Nagla Abdel Karim  1 , Asad Ullah  2 , Peterson Pathrose  3 , Hassana Fathallah  4 , Ashley Perry  4 , John C Morris  4 , Jiang Wang  5 , Sandra L Starnes  3

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline J Clin Oncol. 2022 Jul 11;JCO2200825. doi: 10.1200/JCO.22.00825. Online ahead of print. Navneet Singh  1 , Sarah Temin  2 , Sherman Baker Jr  3 , et al.

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States Oncologist. 2022 Jul 4;oyac116. doi: 10.1093/oncolo/oyac116. Online ahead of print. Mohammad Jahanzeb  1 , Huamao M Lin  2 , Yanyu Wu  2 , Pingkuan Zhang  2 , Magdaliz Gorritz  3 , Catherine B McGuiness 3 , Wei-Ti Huang 3, Kainan Sun 3 , Chi-Chang Chen  3 , D Ross Camidge  4

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L Curr Med Res Opin. 2022 Jul 11;1-24. doi: 10.1080/03007995.2022.2100653. Online ahead of print. Karen L Reckamp  1 , Huamao M Lin  2 , Holly Cranmer  3 , Yanyu Wu  2 , Pingkuan Zhang  2 , Stephen Kay  4 , Laura J Walton  5 , Junwu Shen  2 , Sanjay Popat  6 , D Ross Camidge  7

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer Thorac Cancer. 2022 Jul 11. doi: 10.1111/1759-7714.14568. Online ahead of print. Da Hyun Kang  1 , Seong-Woo Choi  1 , Pureum Sun  2 , Chaeuk Chung  1 , Dongil Park  1 , Song-I Lee  1 , Jeong Suk Koh  1 , Yoonjoo Kim  1 , Jeong Eun Lee  1

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline J Clin Oncol. 2022 Jul 11;JCO2200824. doi: 10.1200/JCO.22.00824. Online ahead of print. Navneet Singh  1 , Sarah Temin  2 , Sherman Baker Jr  3 , et al.

Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration Transl Lung Cancer Res. 2022 Jun;11(6):964-974. doi: 10.21037/tlcr-22-22. Guanghui Gao #  1 , Jian Ni #  1 , Yina Wang  2 , et al.

Non-small cell lung cancer in the era of immunotherapy Semin Oncol. 2022 Jul 8;S0093-7754(22)00049-5. doi: 10.1053/j.seminoncol.2022.06.009. Online ahead of print. Quillan Huang  1 , Jan Kemnade  1 , Loraine Cornwell  2 , Farrah Kheradmand  3 , Anita L Sabichi  4 , Devika Das  5

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib JTO Clin Res Rep. 2022 Jun 8;3(7):100347. doi: 10.1016/j.jtocrr.2022.100347. eCollection 2022 Jul. Jaime L Schneider  1   2 , Alona Muzikansky  1 , Jessica J Lin  1   2 , Elizabeth A Krueger  1 , Inga T Lennes  1   2 , Joseph O Jacobson  3 , Michael Cheng  3 , Rebecca S Heist  1   2 , Zofia Piotrowska  1   2 , Justin F Gainor  1   2 , Alice T Shaw  1   2 , Ibiay Dagogo-Jack  1   2

NSCLC - RADIOTHERAPY

Patient and Treatment Factors Associated with Improved Local Control and Survival in Oligometastatic Bone Disease: Results from a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy Int J Radiat Oncol Biol Phys. 2022 Jul 12;S0360-3016(22)00713-1. doi: 10.1016/j.ijrobp.2022.06.096. Online ahead of print. Maria C Thomas  1 , Yu-Hui Chen  2 , Elliot Fite  3 , Andrew Pangilinan  3 , Katerina Bubelo  3 , Alexander Spektor  3 , Tracy A Balboni  3 , Mai Anh Huynh  4

Real world use of radiation for newly diagnosed brain metastases in ALK-positive lung cancer receiving a first line ALK inhibitor Int J Radiat Oncol Biol Phys. 2022 Jul 20;S0360-3016(22)00730-1. doi: 10.1016/j.ijrobp.2022.07.010. Online ahead of print. Sameera Kumar  1 , Xiaoliang Wang  2 , Harlan Pittell  2 , Gregory S Calip  3 , Stephanie E Weiss  1 , Joshua E Meyer  1 , Trevor J Royce  4

Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer Pract Radiat Oncol. 2022 Jul 17;S1879-8500(22)00208-9. doi: 10.1016/j.prro.2022.06.013. Online ahead of print. Max Devine  1 , David J Merriott  2 , Hyunsoo J No  1 , et al.

Stereotactic Body Radiation Therapy For Metastases In Long Bones Int J Radiat Oncol Biol Phys. 2022 Jul 15;S0360-3016(22)00723-4. doi: 10.1016/j.ijrobp.2022.07.003. Online ahead of print. Indira Madani  1 , Arjun Sahgal  2 , et al.

Sociodemographic and Clinical Factors Associated with Radiation Treatment Nonadherence and Survival among Rural and Nonrural Cancer Patients Int J Radiat Oncol Biol Phys. 2022 Jun 28;S0360-3016(22)00638-1. doi: 10.1016/j.ijrobp.2022.06.075. Online ahead of print. Bonny B Morris 1 , Ryan Hughes  2 , Emma C Fields  3 , Roy T Sabo  4 , Kathryn E Weaver  5 , Bernard F Fuemmeler  6

Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung Lung Cancer. 2022 Jun 30;170:185-193. doi: 10.1016/j.lungcan.2022.06.014. Online ahead of print. Therese Mj Kang  1 , Nicholas Hardcastle  2 , Anurag K Singh  3 , et al.

Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer Cancers (Basel). 2022 Jun 27;14(13):3144. doi: 10.3390/cancers14133144. Alexander Chi  1   2 , Nam P Nguyen  3

SMALL CELL LUNG CANCER - SCLC

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study JTO Clin Res Rep. 2022 Jun 8;3(7):100353. doi: 10.1016/j.jtocrr.2022.100353. eCollection 2022 Jul. Kenji Morimoto  1 , Tadaaki Yamada  1 , Takayuki Takeda  2 , et al.

Impact of Socioeconomic Factors on Overall Survival in SCLC TO Clin Res Rep. 2022 Jun 18;3(7):100360. doi: 10.1016/j.jtocrr.2022.100360. eCollection 2022 Jul. Logan Roof  1 , Wei Wei  1 , Katherine Tullio  1 , Nathan A Pennell  1 , James P Stevenson  1

Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma Eur J Cancer. 2022 Jul 11;172:357-366. doi: 10.1016/j.ejca.2022.06.020. Online ahead of print. Daphne W Dumoulin  1 , Luca Cantini  2 , Robin Cornelissen  1 , et al.

Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens Semin Oncol. 2022 Jul 2;S0093-7754(22)00043-4. doi: 10.1053/j.seminoncol.2022.06.003. Online ahead of print. Joseph B Hiatt  1 , Perrin E Romine  2 , Daniel Y Wu  3

Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer Clin Drug Investig. 2022 Jul 16. doi: 10.1007/s40261-022-01179-x. Online ahead of print. Chao Li  1   2 , Janet K Horton  1 , Mark Sale  3 , Laura Curd  3 , Vineet Goti  3   4 , Wenli Tao  1   5 , Andrew Beelen  6

PALLIATIVE AND SUPPORTIVE CARE

“The whole of humanity has lungs, doesn’t it? We are not all the same sort of people”: patient preferences and choices for an online, self-guided chronic breathlessness supportive intervention: SELF-BREATHE ERJ Open Res. 2022 Jul 11;8(3):00093-2022. doi: 10.1183/23120541.00093-2022. eCollection 2022 Jul. Charles C Reilly  1   2 , Katherine Bristowe  2 , Anna Roach  2 , Trudie Chalder  3 , Matthew Maddocks  2 , Irene J Higginson  2

The Impact of Mindfulness-Based Stress Reduction (MBSR) on Psychological Outcomes and Quality of Life in Patients With Lung Cancer: A Meta-Analysis Front Psychol. 2022 Jun 28;13:901247. doi: 10.3389/fpsyg.2022.901247. eCollection 2022. Xu Tian  1 , Li-Juan Yi  2 , Chen-Si-Sheng Liang  3 , Lei Gu  4 , Chang Peng  5 , Gui-Hua Chen  6 , Maria F Jiménez-Herrera  1

Immune checkpoint inhibitor-related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease Histopathology. 2022 Jul 1. doi: 10.1111/his.14704. Online ahead of print. Saira Imran #  1 , Andrew Golden #  2 , Marc Feinstein  1 , Andrew Plodkowski  3 , Francis Bodd  2 , Natasha Rekhtman  2 , William D Travis 2 , Diane E Stover  1 , Jennifer L Sauter  2

Clinical and economic value of oral nutrition supplements in patients with cancer: a position paper from the Survivorship Care and Nutritional Support Working Group of Alliance Against Cancer. Support Care Cancer. 2022 Jul 6. doi: 10.1007/s00520-022-07269-y. Online ahead of print. Riccardo Caccialanza  1 , Alessandro Laviano  2 , Cristina Bosetti  3 , Mariateresa Nardi  4 ,Valentina Casalone  5 , Lucilla Titta  6 , Roberto Mele  7 , Giovanni De Pergola  8 , Francesco De Lorenzo  9 , Paolo Pedrazzoli  10 , Alliance Against Cancer (ACC) Survivorship Care, Nutritional Support Working Group

COMPLEMENTARY & ALTERNATIVE THERAPY

Clinical efficacy and safety of NSCLC ancillary treatment with compound Kushen injection through immunocompetence regulation: A systematic review and meta-analysis Phytomedicine. 2022 Jul 6;104:154315. doi: 10.1016/j.phymed.2022.154315. Online ahead of print. Dan Wang  1, Yong Xu 2 , Tongxing Huang 1 , Wenpan Peng 3 , Dongwei Zhu 1 , Xianmei Zhou 4 , Qi Wu  5

Effects and mechanisms of resveratrol for prevention and management of cancers: An updated review Crit Rev Food Sci Nutr. 2022 Jul 19;1-19. doi: 10.1080/10408398.2022.2101428. Online ahead of print. Si-Xia Wu  1 , Ruo-Gu Xiong  1 , Si-Yu Huang  1 , Dan-Dan Zhou  1 , Adila Saimaiti  1 , Cai-Ning Zhao  2 , Ao Shang  3 , Yun-Jian Zhang  4 , Ren-You Gan  5 , Hua-Bin Li  1

MISCELLANEOUS WORKS

The effect of smoking on survival in lung carcinoma patients with brain metastasis: a systematic review and meta-analysis Neurosurg Rev. 2022 Jul 14. doi: 10.1007/s10143-022-01832-1. Online ahead of print. Shreya Chawla  1   2 , Ishaan A Tewarie  3   4   5 , Qingwei O Zhang  6 , Alexander F C Hulsbergen  2   7   8 , Rania A Mekary  2   9 , Marike L D Broekman  7   8   10

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer Curr Oncol. 2022 Jul 15;29(7):4981-4997. doi: 10.3390/curroncol29070396. Diana N Ionescu  1 , Tracy L Stockley  2   3 , et al.

Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China Front Oncol. 2022 Jun 6;12:819674. doi: 10.3389/fonc.2022.819674. eCollection 2022. Haijing Guan  1  2 , Chunping Wang 3 , Chen Chen  2   4 , Sheng Han  3 , Zhigang Zhao  1

Tribal Tobacco Use Project II: Planning, Implementation, and Dissemination Using Culturally Relevant Data Collection among American Indian Communities Int J Environ Res Public Health. 2022 Jun 23;19(13):7708. doi: 10.3390/ijerph19137708. Kendra M Roland  1 , Madison D Anderson  1   2 , Dana M Carroll  3 , Anna G Webber  1 , Kristine L Rhodes  4 , John Poupart  5 , Jean L Forster  2 , Melanie Peterson-Hickey  6 , Wyatt J Pickner  1

Impacts of Medicaid Expansion on Stage at Cancer Diagnosis by Patient Insurance Type Am J Prev Med. 2022 Jul 20;S0749-3797(22)00325-7. doi: 10.1016/j.amepre.2022.06.001. Online ahead of print. Kristin M Primm  1 , Sarah P Huepenbecker  2 , Hui Zhao  3 , Charlotte C Sun  2 , Daphne C Hernandez  4 , Larissa A Meyer  2 , Shine Chang  5

Archives